Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.
Profitability
This table compares Entrada Therapeutics and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
| Dianthus Therapeutics | -7,436.50% | -19.68% | -18.95% |
Valuation & Earnings
This table compares Entrada Therapeutics and Dianthus Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $25.42 million | 7.84 | -$143.75 million | ($3.84) | -1.33 |
| Dianthus Therapeutics | $2.04 million | 2,534.23 | -$162.34 million | ($3.99) | -23.01 |
Entrada Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Entrada Therapeutics has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Entrada Therapeutics and Dianthus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Dianthus Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
Entrada Therapeutics presently has a consensus price target of $17.75, suggesting a potential upside of 248.72%. Dianthus Therapeutics has a consensus price target of $128.77, suggesting a potential upside of 40.26%. Given Entrada Therapeutics’ higher probable upside, research analysts clearly believe Entrada Therapeutics is more favorable than Dianthus Therapeutics.
Institutional and Insider Ownership
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Entrada Therapeutics beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
